Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-12
2008-08-12
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S371000
Reexamination Certificate
active
07411071
ABSTRACT:
A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I):where X is S, O or N; Z is —T—COOR1or —T—COR1; and T, R, R1, Ra, Rb, Rc, Rd, Z, A and B are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
REFERENCES:
patent: 3317387 (1967-05-01), Prichard
patent: 3422104 (1969-01-01), Schröter et al.
patent: 3517073 (1970-06-01), Fields
patent: 4786646 (1988-11-01), Guthrie et al.
patent: 5055468 (1991-10-01), Gray et al.
patent: 5202486 (1993-04-01), Barrish et al.
patent: 5332820 (1994-07-01), Duncia
patent: 5409932 (1995-04-01), Schwenner et al.
patent: 5411960 (1995-05-01), Schwenner et al.
patent: 5455248 (1995-10-01), DeHaven-Hudkins et al.
patent: 5514683 (1996-05-01), Kalindjian et al.
patent: 5569655 (1996-10-01), Dority, Jr. et al.
patent: 5616780 (1997-04-01), Pitteloud et al.
patent: 6214915 (2001-04-01), Avakian et al.
patent: 6262059 (2001-07-01), Pamukcu et al.
patent: 6291679 (2001-09-01), Mailliet et al.
patent: 6995181 (2006-02-01), Vaccaro et al.
patent: 2005/0182110 (2005-08-01), Yang
patent: 198 678 (1982-11-01), None
patent: 197 42 014 (1999-03-01), None
patent: 0 405 436 (1995-11-01), None
patent: WO 93/16982 (1993-09-01), None
patent: WO 94/00421 (1994-01-01), None
patent: WO 95/05359 (1995-02-01), None
patent: WO 95/15947 (1995-06-01), None
patent: WO 99/15493 (1999-04-01), None
patent: WO 02/051851 (2002-07-01), None
patent: WO 03/062241 (2003-07-01), None
patent: WO 03/101932 (2003-12-01), None
patent: WO 03/104195 (2003-12-01), None
patent: WO 2004/000869 (2003-12-01), None
patent: WO 2004/005229 (2004-01-01), None
patent: WO 2004/009017 (2004-01-01), None
patent: WO 2005/070207 (2005-08-01), None
patent: WO 2005/072729 (2005-08-01), None
patent: WO 2005/072732 (2005-08-01), None
patent: WO 2005/073221 (2005-08-01), None
patent: 681802 (1968-03-01), None
Alibert, S. et al., “Synthesis and Effects on Chloroquine Susceptibility inPlasmodium falciparumof a Series of New Dihydroanthracene Derivatives”, Journal of Medicinal Chemistry, vol. 45, No. 15, pp. 3195-3209 (2002).
Baldwin, Jr., A.S., “The transcription factor NF-κB and human disease”, The Journal of Clinical Investigation, vol. 107, No. 1, pp. 3-6 (2001).
Bradsher, C.K. et al., “Acridizinium Ion Chemistry. II. The Diels-Alder Reaction”, Journal of the American Chemical Society, vol. 80, pp. 933-934 (1958).
Bradsher, C.K. et al., “Addition of Dienophiles to the Acridizinium Ion. III. Evidence for a Two-Step Reaction”, The Journal of Organic Chemistry, vol. 34, No. 6, pp. 1700-1702 (1969).
Bradsher, C.K. et al., “Cationic Polar Cycloaddition of Cyclopropenes”, J. Org. Chem., vol. 44, No. 8, pp. 1199-1202 (1979).
Bradsher, C.K. et al., “Possible Role of Charge-Transfer Complexes in Cationic Polar Cycloaddition”, J. Org. Chem., vol. 43, No. 5, pp. 822-827 (1978).
Bradsher, C.K. et al., “Stereoselectivity Due to Electrostatic Repulsion in the Polar Cycloaddition of the Acridizinium Ion”, J. Het. Chem., vol. 10, pp. 1031-1033 (1973).
Bradsher, C.K. et al., “Steric Effects in Some Cycloaddition Reactions”, Journal of the American Chemical Society, vol. 99, No. 8, pp. 2588-2591 (1977).
Bradsher, C.K. et al., “The Nature of the Addition of Dienophiles to the Acridizinium Ion”, The Journal of Organic Chemistry, vol. 33, No. 2, pp. 519-523 (1968).
Burke, J.R., “Targeting IκB kinase for the treatment of inflammatory and other disorders”, Current Opinion in Drug Discovery & Development, vol. 6, No. 5, pp. 720-728 (2003).
Burnham, W.S. et al., “6,11-Dihydroacridizinium Derivatives Having a 6,11-Etheno Bridge”, J. Org. Chem., vol. 37, No. 3, pp. 355-358 (1972).
Butler, D.N. et al., “Chemistry of Proximal π-Bond Systems. Part I. Synthesis of Vicinal Exocyclic Dimethylene Hydrocarbons”, Canadian Journal of Chemistry, vol. 50, pp. 795-802 (1972).
Caldenhoven, E. et al., “Negative Cross-Talk ReIA and the Glucocorticoid Receptor: A Possible Mechanism for the Antiinflammatory Action of Glucocorticoids”, Molecular Endocrinology, vol. 9, No. 4, pp. 401-412 (1995).
Chakravarti, D. et al., “Role of CBP/P300 in nuclear receptor signalling”, Nature, vol. 383, pp. 99-103 (1996).
Compounds (by Registry Number) with no references in the Chemical Abstracts file: 500280-08-0, 496959-82-1, 332907-97-8, 331751-07-6, 331427-65-7, 312317-98-9, 312315-55-2, 311331-77-8, year not available.
Diamond, M.I. et al., “Transcription Factor Interactions: Selectors of Positive or Negative Regulation from a Single DNA Element”, Science, vol. 249, pp. 1266-1272 (1990).
El-Zanfally, S. et al., “Reactions of Aminopyridines with some Inner Anhydrides”, Egypt J. Pharm. Sci., vol. 17, No. 3, pp. 53-62 (1976).
Fields, D.L., “A Novel Synthesis of 2-Naphthols, Phenanthrols, Anthracenes, and Other Polycyclic Aromatic Products”, J. Org. Chem., vol. 36, No. 20, pp. 3002-3005 (1971).
Fields, D.L. et al., “Azonia Polycyclic Quinoneso-Diazo-Oxides and Related Products”, J. Het. Chem., vol. 7, pp. 91-97 (1970).
Fields, D.L. et al., “Cleavage Reactions of Bicyclic Ketones Derived from Azoniaanthracene-Ketene Acetal Adducts”, J. Org. Chem., vol. 35, No. 6, pp. 1870-1785 (1970).
Fields, D.L. et al., “Diels-Alder Reactions Involving Azonia Polycyclic Aromatic Compounds and Nucleophilic Dienophiles”, J. Org. Chem., vol. 33, No. 1, pp. 390-395 (1968).
Fields, D.L. et al., “Overcrowded Molecules. I. Substituted 8-tert-Butyl-1-(2-pyridyl)naphthalenes, Including a Thermodynamically Stable Ketonic Tautomer”, J. Org. Chem., vol. 36, No. 20, pp. 2986-2990 (1971).
Fields, D.L. et al., “Overcrowded Molecules: II. 4,5-Bis(2-pyridyl)phenanthrene-3,6-diols”, J. Org. Chem., vol. 36, No. 20, pp. 2991-2995 (1971).
Fields, D.L. et al., “Overcrowded Molecules. III. 13,14-Bis(2-pyridyl)pentaphene and Related Compounds”, J. Org. Chem., vol. 36, No. 20, pp. 2995-3001 (1971).
Firestein, G.S. et al., “Signal Transduction and Transcription Factors in Rheumatic Disease”, Arthritis & Rheumatism, vol. 42, No. 4, pp. 609-621 (1999).
Hart, H. et al., “1,4,5,8,9-pentamethylanthracene, Synthesis and Protonation”, Tetrahedron Letters, vol. 16, No. 52, pp. 4639-4642 (1975).
Jackson, R.W. et al., “Benzobicyclooctanes as Novel Inhibitors of TNF-α Signaling”, Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 1093-1097 (2002).
Jonat, C. et al., “Antitumor Promotion and Antiinflammation: Down-Modulation of AP-1 (Fos/Jun) Activity by Glucocorticoid Hormone”, Cell, vol. 62, pp. 1189-1204 (1990).
Kamei, Y. et al., “A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors”, Cell, vol. 85, pp. 403-414 (1996).
Kotha, S. et al., “Synthesis of highly constrained unusual α-amino acid derivative by the Diels-Alder approach”, Indian Journal of Chemistry, vol. 41B, pp. 2330-2332 (2002).
Manning, A.M. et al., “Targeting JNK for Therapeutic Benefit: From Junk to Gold”, Nature Reviews Drug Discovery, vol. 2, pp. 554-565 (2003).
Miesfeld, R. et al., “Characterization of a steroid hormone receptor gene and mRNA in wild-type and mutant cells”, Nature, vol. 312, pp. 779-781 (1984).
Parham, M.E. et al., “The Cycloaddition of the Acridizinium Ion with Norbornene Derivatives”, J. Org. Chem., vol. 37, No. 3, pp. 358-362 (1972).
Peltz, G., “Transcription factors in immune-mediated disease”, Current
Doweyko Arthur M.
Doweyko Lidia M.
Yang Bingwei V.
Bristol--Myers Squibb Company
Duncan Laurelee A.
Stockton Laura L.
LandOfFree
Modulators of the glucocorticoid receptor, AP-1, and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of the glucocorticoid receptor, AP-1, and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of the glucocorticoid receptor, AP-1, and/or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4006662